

Discover MycarinGstudy

A clinical research study for adults living with myasthenia gravis (MG)

mycaringstudy.com

The **MycarinGstudy** is a clinical research study to evaluate the efficacy and safety of rozanolixizumab (an investigational subcutaneously administered monoclonal IgG antibody) in adults with generalized MG. Rozanolixizumab is an investigational medicine and is not approved by any Health Authority for any indication.

Individuals may be eligible for the **MycarinGstudy** if...

- ✓ They are age 18 or older and have a diagnosis of generalized MG
- ✓ They have moderate to severe MG symptoms involving more than just the eyes
- ✓ Their doctor decides they meet these and other eligibility criteria

Interested individuals can speak to their physician about participating in this research study.



More information about the **MycarinGstudy**:

Type of study	Phase III, randomized, double-blind, placebo-controlled
Primary objective	Assesses efficacy as measured by changes in Myasthenia Gravis - Activities of Daily Living score
Randomization	Randomized into one of two dosage regimen groups or a placebo group
Method of administration	Subcutaneous (under the skin) infusion, 6 doses given once per week
Duration of study participation	<p>18 weeks, consisting of the following:</p> <ul style="list-style-type: none">• Screening (up to 4 weeks) and randomization• Study treatment period (6 weeks)• Observation period (8 weeks) <p>After this time, eligible participants will be invited to take part in a separate long-term open-label extension study, with an additional study treatment period of 52 weeks where they will receive rozanolixizumab</p>




Inspired by **patients**.
Driven by **science**.

My
caringG
Study



Locations involved in the **MycarinG**study

In the USA, the states currently recruiting participants include:



- Arizona (Phoenix)
- California (Los Angeles, San Francisco)
- Colorado (Aurora)
- Connecticut (New Britain)
- District of Columbia (Washington)
- Florida (Miami, Tampa)
- Georgia (Augusta)
- Indiana (Indianapolis)
- Kansas (Fairway)
- Kentucky (Lexington)
- Ohio (Centerville, Columbus)
- Pennsylvania (Philadelphia)
- South Carolina (Charleston)
- Texas (Houston)



Where
to next?

This list is regularly updated; the latest locations are available at **mycaringstudy.com/locations**.

The study is also being conducted in Belgium, Canada and Spain.

Individuals who are interested in learning more about eligibility and to find a study site may visit **mycaringstudy.com** or contact UCB by emailing **UCBCares@ucb.com**.

Rozanolixizumab is an investigational medicine and is not approved by any Health Authority for any indication.

© 2020 UCB Group of Companies. All rights reserved. US-S-RZ-MG-2000001. Date of preparation: April 2020